The Efficacy of Cinacalcet in the Treatment of Hyperparathyroidism in Turkish Hemodialysis Patient Population

OBJECTIVE: Cinacalcet reduces parathyroid hormone levels by increasing the sensitivity of the parathyroid gland to calcium. In this study, we firstly aimed to evaluate the efficacy of cinacalcet in Turkish hemodialysis patients. MATERIAL and METHODS: 4483 hemodialysis patients were screened and 469 patients who had used cinacalcet were included in the study. The patients were divided into 4 groups according to drug usage durations (Group 1: 3 months, Group 2: 6 months, Group 3: 9 months and Group 4: 12 months). The patients’ Parathormone, Ca, P and CaxP levels at the 3rd, 6th, 9th and 12th months were compared to the start of treatment and previous months. RESULTS: The levels of Parathormone, Ca, P and CaxP significantly decreased compared to their initial levels in all groups (from 1412 pg/ml to 1222 pg/mL for Parathormone, p<0,001) in the 3rd month. However, this reduction was not continued in the subsequent months (Parathormone: 1381 pg/ ml for the 12th month).

[1]  J. Wetmore,et al.  A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[2]  S. Fukuhara,et al.  Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan , 2013, Kidney international supplements.

[3]  M. Vervloet,et al.  Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality? , 2013, The Netherlands journal of medicine.

[4]  M. Tonelli,et al.  Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomized Controlled Trials , 2013, PLoS medicine.

[5]  J. Chen,et al.  Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis , 2012, PLoS ONE.

[6]  L. Lucchi,et al.  Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. , 2011, Artificial organs.

[7]  John Cunningham,et al.  Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[8]  K. Ateş,et al.  Current Status of Renal Replacement Therapy in Turkey: A Summary of Turkish Society of Nephrology 2014 Annual Registry Report , 2011 .

[9]  T. Urbanek,et al.  Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? , 2010, Kidney and Blood Pressure Research.

[10]  M. Vervloet,et al.  Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  D. Goldsmith,et al.  Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[13]  B. Culleton,et al.  Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. , 2005, Journal of the American Society of Nephrology : JASN.

[14]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[15]  D. Lacey,et al.  Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  S. Moe,et al.  Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product , 2003, American Journal of Nephrology.

[17]  S. Rosansky,et al.  The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[18]  W. Goodman,et al.  The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. , 2002, Journal of the American Society of Nephrology : JASN.